Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic profiling of canine (dog) serum and urine

ABSTRACT: Companion dog care market is annually increasing. A relationship with a dog who lives with humans gives a lot of psychological stability. Therefore, companion dog's health is important to the owner. It would be of great help if a non-invasive method could monitor health through bodily fluids (urine, serum). In addition to this, it is principal to discover and verify protein biomarkers that can detect the presence or absence of disease. Despite the growing application of proteomics in biomarker research using canine serum or urine, there is no spectral assay library publicly available. Here, we set up spectral assay libraries for canine serum and urine samples using 24 midpH-fractionated samples to enable deep proteome coverage. The canine serum assay library includes 4,749 protein groups and 25,228 peptides and urine assay library contains 1,132 protein groups and 5,483 peptides.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Canis Familiaris (dog) (canis Lupus Familiaris)

TISSUE(S): Urine, Blood Serum

SUBMITTER: Kyunggon Kim

LAB HEAD: Kyunggon Kim

PROVIDER: PXD034770 | Pride | 2023-04-05

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Similar Datasets

Proteomic profiling of canine (dog) serum and urine

Project description:Companion dog care market is annually increasing. A relationship with a dog who lives with humans gives a lot of psychological stability. Therefore, companion dog's health is important to the owner. It would be of great help if a non-invasive method could monitor health through bodily fluids (urine, serum). In addition to this, it is principal to discover and verify protein biomarkers that can detect the presence or absence of disease. Despite the growing application of proteomics in biomarker research using canine serum or urine, there is no spectral assay library publicly available. Here, we set up spectral assay libraries for canine serum and urine samples using 24 midpH-fractionated samples to enable deep proteome coverage. The canine serum assay library includes 4,749 protein groups and 25,228 peptides and urine assay library contains 1,132 protein groups and 5,483 peptides.

2023-09-04 | PXD038645 | Pride

Profiling of urinary microRNAs in children with atopic dermatitis

Project description:Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease in children characterized by dermatitis and pruritus. MicroRNAs (miRNAs) have been shown as great potential biomarkers for disease fingerprints to predict prognostics. We aimed to identify miRNA signature from serum and urine for the prognosis of AD patient by genome-wide miRNA profiling analysis. Urine from 3 children with AD and 3 healthy children were collected

2014-10-17 | E-GEOD-62403 | biostudies-arrayexpress

Profiling of serum microRNAs in children with atopic dermatitis

Project description:Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease in children characterized by dermatitis and pruritus. MicroRNAs (miRNAs) have been shown as great potential biomarkers for disease fingerprints to predict prognostics. We aimed to identify miRNA signature from serum and urine for the prognosis of AD patient by genome-wide miRNA profiling analysis. Serum from 8 children with AD and 8 healthy children were collected

2014-10-17 | E-GEOD-62404 | biostudies-arrayexpress

Transcription profiling of E. coli strains CFT073, Nissle 1917 and 83972 grown exponentially in MOPS, exponentially in human urine and in biofilms in human urine

Project description:Global transcription profiling of E. coli strains CFT073, Nissle 1917 and 83972 grown exponentially in MOPS, exponentially in human urine and in biofilms in human urine.

2010-09-01 | E-MEXP-2609 | biostudies-arrayexpress

Detection of Aggressive Prostate Cancer-Associated Glycoproteins in Urine using Glycoproteomics and Mass Spectrometry

Project description:Clinical management of prostate cancer remains a significant challenge due to the lack of available tests for guiding treatment decisions. The blood Prostate-Specific Antigen (PSA) test has facilitated early detection and intervention of prostate cancer. However, blood PSA levels are less effective in distinguishing aggressive from indolent prostate cancers and other benign prostatic diseases. Thus, the development of novel approaches specific for prostate cancer that can differentiate aggressive from indolent disease remains an urgent medical need. In the current study, we evaluated urine specimens from prostate cancer patients instead of serum using liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the aim of identifying effective prostate cancer biomarkers. Glycoproteins from urine samples of prostate cancer patients with different Gleason scores were characterized via solid phase extraction of N-linked glycosite-containing peptides and LC-MS/MS. In total, 2923 unique glycosite-containing peptides were identified. Comparison of urine-based glycoproteins with those identified from aggressive and non-aggressive prostate cancer tissues as well as sera from prostate cancer patients revealed that the majority of aggressive prostate cancer-associated glycoproteins were more readily detected in patient urine than serum samples. Our data collectively indicate that urine provides a highly reliable source for biomarker testing in patients with aggressive prostate cancer.

2022-02-28 | PXD004495 | Pride

Detection of urinary microRNAs from epithelial ovarian cancer patients as biomarker

Project description:The Urine RNA from 5 ovarian cancer and 5 healthy control were analyzed with the Human miRNA Microarray and then validated with a quantitative reverse-transcription PCR assay with 29 individual samples, 20 benign gynecological disease and 26 age/sex-matched healthy control. This study determines the clinical value of urine miRNAs as biomarker for epithelial ovarian cancer. Results: The miRNA microarray results demonstrate that the original 38 were identified that were significantly differentially expression in epithelial ovarian cancer compared with healthy control (P<0.01). A total of 1 miRNA was up-regulated in ovarian cancer, while 37 miRNA were down-regulated. the urine RNA from 5 ovarian cancer and 5 healthy women were analysised with Human mirRNA microarry

2015-06-17 | E-GEOD-58517 | biostudies-arrayexpress

Transcription profiling of two E. coli ABU strains during biofilm growth in human urine

Project description:Gene expression profiling of two different E. coli ABU strains during biofilm growth in human urine.

2007-02-02 | E-MEXP-926 | biostudies-arrayexpress

Transcription profiling of asymptomatic E. coli strain 83972 grown on urine-agar plates or MOPS-glucose media

Project description:Strain 83972 grown on urine-agar plates compared with MOPS, triplicates.

2011-02-01 | E-MEXP-1453 | biostudies-arrayexpress

Transcription profiling of E. coli CAUTI strains during biofilm growth in human urine

Project description:Gene expression profiling of two different E. coli CAUTI strains during biofilm growth in human urine.<br>

2010-06-09 | E-MEXP-2298 | biostudies-arrayexpress

microRNA expression profiling of urine and cancer tissues of patients with bladder cancer, and those from the controls with haematuria

Project description:Mid-stream urine was collected from bladder cancer patients prior to surgery. Both tumor tissue and normal bladder mucosa that are located at >3cm away from the tumor edge were obtained by cystoscopy. For the normal controls with haematuria, urine samples were collected from patients who had normal cystoscopic finding and absence of malignancy with >6 months follow-up. All urine samples were centrifuged at 2500 r.c.f. for 20 minutes and the urine supernatant was collected. Total RNA of urine supernatant and frozen tissue was extracted using MirVanaTM PARISTM Kit (Ambion) in accordance with the manufacturerâs recommended protocols. AgilentTM Human miRNA Microarray Chip (Release 13.0, Agilent Technologies, Santa Clara, CA, USA) was used to determine the microRNA expression profiles of the samples.

2014-04-16 | E-MTAB-2573 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data